EDIT - Editas Medicine, Inc.

QQQ $ 482.33 $ 1.21 (0.25 %)

DIA $ 408.92 $ -0.32 (-0.08 %)

SPY $ 560.61 $ 0.68 (0.12 %)

TLT $ 99.01 $ 0.33 (0.33 %)

GLD $ 232.50 $ 0.84 (0.36 %)

Previous Close

$ 3.96

Open

$ 4.01

Bid

$ 4.06 x 118

Ask

$ 4.07 x 1,018

Day's Range

$ 3.96 - $ 4.14

52 Week Range

$ 3.71 - $ 11.69

Volume

1,127,851

Average Volume

Market Cap

325.95M

Beta (5Y Monthly)

$ 1.49

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2024	06-30-2024	10-Q
2	05-08-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-03-2023	09-30-2023	10-Q
5	08-02-2023	06-30-2023	10-Q
6	05-05-2023	03-31-2023	10-Q
7	02-22-2023	12-31-2022	10-K
8	11-02-2022	09-30-2022	10-Q
9	08-03-2022	06-30-2022	10-Q
10	05-04-2022	03-31-2022	10-Q
11	02-24-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-06-2020	09-30-2020	10-Q
17	08-07-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	02-26-2020	12-31-2019	10-K
20	11-12-2019	09-30-2019	10-Q
21	08-07-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	03-01-2019	12-31-2018	10-K
24	11-08-2018	09-30-2018	10-Q
25	08-07-2018	06-30-2018	10-Q
26	05-04-2018	03-31-2018	10-Q
27	03-08-2018	12-31-2017	10-K
28	11-08-2017	09-30-2017	10-Q
29	08-09-2017	06-30-2017	10-Q
30	05-15-2017	03-31-2017	10-Q
31	03-03-2017	12-31-2016	10-K
32	11-09-2016	09-30-2016	10-Q
33	08-10-2016	06-30-2016	10-Q
34	05-13-2016	03-31-2016	10-Q
35	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Barclays Maintains Equal-Weight on Editas ...
08/08/2024 18:44:28

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $9 t...

Truist Securities Maintains Buy on Editas ...
08/08/2024 12:35:17

Truist Securities analyst Joon Lee maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $20 t...

boot-barn-to-rally-around-27-here-are-10-top-analyst-forecasts-for-thursday

Boot Barn To Rally Around 27%? Here Are 10...
08/08/2024 12:13:21

B of A Securities Upgrades Editas Medicine...
08/08/2024 11:11:09

B of A Securities analyst Greg Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and raises the price targ...

Editas Medicine' Cash Balance Of $318.3M I...
08/07/2024 11:06:23

Editas Medicine Q2 2024 GAAP EPS $(0.82) M...
08/07/2024 11:03:58

Unveiling 5 Analyst Insights On Editas Med...
06/18/2024 17:00:48

Oppenheimer Maintains Perform on Editas Me...
06/18/2024 16:46:34

Oppenheimer analyst Jay Olson maintains Editas Medicine (NASDAQ:EDIT) with a Perform and maintains $12 price target.

Editas Medicine Unveils Updated Safety And...
06/14/2024 08:12:53

All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-fr...

Editas Medicine Reveals Updated Safety And...
06/14/2024 08:11:53

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusi...

The Analyst Verdict: Editas Medicine In Th...
05/30/2024 16:00:14

Evercore ISI Group Maintains In-Line on Ed...
05/30/2024 15:14:49

Evercore ISI Group analyst Liisa Bayko maintains Editas Medicine (NASDAQ:EDIT) with a In-Line and lowers the price target fr...

Editas Medicine To Present Clinical Data F...
05/14/2024 14:10:26

Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one o...

Editas Medicine Reports Presentation Of Pr...
05/10/2024 10:06:44

The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Ce...

Citigroup Maintains Buy on Editas Medicine...
05/09/2024 18:05:16

Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $16 ...

Morgan Stanley Upgrades Editas Medicine to...
05/09/2024 16:41:38

Morgan Stanley analyst Matthew Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and announce...

Barclays Maintains Equal-Weight on Editas ...
05/09/2024 15:05:39

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $11 ...

Editas Medicine Q1 2024 Adj EPS $(0.76) Mi...
05/08/2024 11:04:15

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0...

Editas Medicine Announced A Two-year Exten...
05/01/2024 12:09:34

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...

Editas Medicine To Present Pre-Clinical Da...
04/22/2024 20:33:55

Editas Medicine presentations at ASGCT include:Oral presentation of in vivo pre-clinical data from mouse studies using lipid na...